Boston Scientific Forecasts Flattened Growth Through 2027 Amid Cyberattack and Product Headwinds
During its third-quarter 2026 earnings call, Boston Scientific (BSX) announced that sales and earnings growth are expected to flatten through 2027. The company cited an eight-day network outage caused by a cyber incident that disrupted shipments, alongside market share erosion in electrophysiology and left atrial appendage closure procedures as primary drivers for the slowdown. To mitigate margin compression and pricing pressures in China, management is implementing corporate restructuring and supply chain overhauls to improve efficiency. Despite near-term stagnation, leadership remains focused on long-term expansion through pulsed-field ablation technologies and cardiovascular platforms, targeting $25 billion in new market opportunities by 2030.
Topics: corporate restructuring cybersecurity incident earnings report product pipeline revenue guidance